ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Evaluation of the anti-apoptotic, anti-platelet aggregation, and pro-angiogenic properties of Naoshuantong capsule in ischemic stroke: insights from network pharmacology and animal experiments.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo explore the complex molecular mechanisms of Naoshuantong capsule (, NST), a Traditional Chinese Medicine formula, against ischemic stroke (IS) using network pharmacology and various experimental verifications.
methodsThis study employed an integrative approach that combined network pharmacology with experimental validation. Specifically, a network pharmacology model was developed to clarify the fundamental mechanisms and essential NST targets against IS. The core targets and pathways were verified using molecular docking and animal experiments. Additionally, the predicted effects of NST were confirmed by a series of experimental techniques, including hematoxylin-eosin staining, platelet aggregation, flow cytometry, and Western blotting.
resultsA total of 299 targets for overlap of compounds-disease targets were predicted. Protein-protein interaction (PPI) network analysis revealed that the top 30 core targets. Subsequent molecular docking analysis demonstrated that serine-threonine protein kinase 1 (AKT1), phosphoinositide 3-kinase (PI3K), and vascular endothelial growth factor A (VEGFA) have significant binding abilities with these compounds. Gene ontology (GO) enrichment analysis indicated that NST mechanisms against IS involved anti-apoptosis, antiplatelet-aggregation, and angiogenesis ability, confirmed by animal experiments. GO pathway analysis further showed that the mechanism of NST in treating IS was associated PI3K-AKT signaling. Ultimately, this study determined that NST downregulated cleaved-caspase-3 expression while upregulated phosphorylated AKT (P-AKT)/AKT, phosphatidylinositol-4,5-Bisphosphate 3-kinase/PI3K, B-cell lymphoma-2 (Bcl-2)/Bcl-2-associated X protein, and VEGFA expressions.
conclusionThe analysis utilizing multiple approaches manifested that NST has anti-apoptotic, antiplatelet-aggregation, and pro-angiogenic properties in managing IS, offering a systemic outlook for investigating the impact of NST on IS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.